Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)
9.10
+0.28 (3.17%)
Aug 20, 2026, 3:00 PM CST
SHA:603520 Revenue
Zhejiang Starry Pharmaceutical had revenue of 711.27M CNY in the quarter ending March 31, 2026, with 3.70% growth. This brings the company's revenue in the last twelve months to 2.47B, up 3.23% year-over-year. In the year 2025, Zhejiang Starry Pharmaceutical had annual revenue of 2.45B with 4.07% growth.
Revenue (ttm)
2.47B
Revenue Growth
+3.23%
P/S Ratio
1.61
Revenue / Employee
1.30M
Employees
1,905
Market Cap
3.99B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.45B | 95.55M | 4.07% |
| Dec 31, 2024 | 2.35B | 154.24M | 7.02% |
| Dec 31, 2023 | 2.20B | 64.75M | 3.04% |
| Dec 31, 2022 | 2.13B | 131.32M | 6.57% |
| Dec 31, 2021 | 2.00B | 632.83M | 46.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jinhe Biotechnology CO., LTD. | 2.99B |
| Nanjing Well Pharmaceutical Group | 1.34B |
| Zhuhai Rundu Pharmaceutical | 1.27B |
| Tibet Weixinkang Medicine | 1.16B |
| Hunan Hansen Pharmaceutical | 1.03B |
| Nanjing Hicin Pharmaceutical | 688.74M |
| Wuhan Hiteck Biological Pharma Co.,Ltd | 543.82M |
| Shanghai Xiao Fang Pharmaceutical | 541.90M |